Video-assisted thoracic surgery (VATS) evaluation of pleural effusions in patients with newly diagnosed advanced ovarian carcinoma can influence the primary management choice for these patients

Gynecologic Oncology

Volumn 116, Issue 3, 2010, Pages 483-488

  Diaz, John P ^a   Abu Rustum, Nadeem R ^a   Sonoda, Yukio ^a   Downey, Robert J ^a   Park, Bernard J ^a   Flores, Raja M ^a   Chang, Kaity ^a   Leitao Jr , Mario M ^a   Barakat, Richard R ^a   Chi, Dennis S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Advanced ovarian carcinoma; Pleural disease; Thracoscopy; VATS

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; SERUM ALBUMIN;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLOGY; CYTOREDUCTIVE SURGERY; DEMOGRAPHY; FEMALE; HUMAN; MEDICAL RECORD REVIEW; OVARY CARCINOMA; PLEURA DISEASE; PLEURA EFFUSION; PRIORITY JOURNAL; SURVIVAL; THORACOSCOPY; THORAX DISEASE; THORAX SURGERY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PLEURAL EFFUSION, MALIGNANT; PLEURAL NEOPLASMS; THORACIC SURGERY, VIDEO-ASSISTED;

EID: 75749083965     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.09.047     Document Type: Article

References (31)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA Cancer J. Clin. 58 (2008) 71-96
2. Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L., and Montz F.J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J. Clin. Oncol. 20 (2002) 1248-1259
3. Bristow R.E., Montz F.J., Lagasse L.D., Leuchter R.S., and Karlan B.Y. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol. Oncol. 72 (1999) 278-287
4. Chi D.S., Eisenhauer E.L., Lang J., Huh J., Haddad L., Abu-Rustum N.R., et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?. Gynecol. Oncol. 103 (2006) 559-564
5. Covens A.L. A critique of surgical cytoreduction in advanced ovarian cancer. Gynecol. Oncol. 78 (2000) 269-274
6. Eisenkop S.M., Spirtos N.M., Montag T.W., Nalick R.H., and Wang H.J. The impact of subspecialty training on the management of advanced ovarian cancer. Gynecol. Oncol. 47 (1992) 203-209
7. Hoskins W.J., McGuire W.P., Brady M.F., Homesley H.D., Creasman W.T., Berman M., et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am. J. Obstet. Gynecol. 170 (1994) 974-979 discussion 979-80
8. Markman M. Concept of optimal surgical cytoreduction in advanced ovarian cancer: a brief critique and a call for action. J. Clin. Oncol. 25 (2007) 4168-4170
9. Piver M.S., and Baker T. The potential for optimal (less than or equal to 2 cm) cytoreductive surgery in advanced ovarian carcinoma at a tertiary medical center: a prospective study. Gynecol. Oncol. 24 (1986) 1-8
10. Piver M.S., Lele S.B., Marchetti D.L., Baker T.R., Tsukada Y., and Emrich L.J. The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma. J. Clin. Oncol. 6 (1988) 983-989
11. Aletti G.D., Dowdy S.C., Podratz K.C., and Cliby W.A. Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. Gynecol. Oncol. 100 (2006) 283-287
12. Brunisholz Y., Miller J., and Proietto A. Stage IV ovarian cancer: a retrospective study on patient's management and outcome in a single institution. Int. J. Gynecol. Cancer 15 (2005) 606-611
13. Curtin J.P., Malik R., Venkatraman E.S., Barakat R.R., and Hoskins W.J. Stage IV ovarian cancer: impact of surgical debulking. Gynecol. Oncol. 64 (1997) 9-12
14. Liu P.C., Benjamin I., Morgan M.A., King S.A., Mikuta J.J., and Rubin S.C. Effect of surgical debulking on survival in stage IV ovarian cancer. Gynecol. Oncol. 64 (1997) 4-8
15. Munkarah A.R., Hallum III A.V., Morris M., Burke T.W., Levenback C., Atkinson E.N., et al. Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer. Gynecol. Oncol. 64 (1997) 13-17
16. Zang R.Y., Zhang Z.Y., Cai S.M., Li Z.T., Chen J., Tang M.Q., et al. Cytoreductive surgery for stage IV epithelial ovarian cancer. J. Exp. Clin. Cancer Res. 18 (1999) 449-454
17. Naik R., Nordin A., Cross P.A., Hemming D., de Barros Lopes A., and Monaghan J.M. Optimal cytoreductive surgery is an independent prognostic indicator in stage IV epithelial ovarian cancer with hepatic metastases. Gynecol. Oncol. 78 (2000) 171-175
18. Akahira J.I., Yoshikawa H., Shimizu Y., Tsunematsu R., Hirakawa T., Kuramoto H., et al. Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. Gynecol. Oncol. 81 (2001) 398-403
19. Bonnefoi H., A'Hern R.P., Fisher C., Macfarlane V., Barton D., Blake P., et al. Natural history of stage IV epithelial ovarian cancer. J. Clin. Oncol. 17 (1999) 767-775
20. Juretzka M.M., Abu-Rustum N.R., Sonoda Y., Downey R.J., Flores R.M., Park B.J., et al. The impact of video-assisted thoracic surgery (VATS) in patients with suspected advanced ovarian malignancies and pleural effusions. Gynecol. Oncol. 104 (2007) 670-674
21. Chi D.S., Abu-Rustum N.R., Sonoda Y., Chen S.W., Flores R.M., Downey R., et al. The benefit of video-assisted thoracoscopic surgery before planned abdominal exploration in patients with suspected advanced ovarian cancer and moderate to large pleural effusions. Gynecol. Oncol. 94 (2004) 307-311
22. FIGO (International Federation of Gynecology and Obstetrics) 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006;95 Suppl 1: S1-257.
23. Goodman H.M., Harlow B.L., Sheets E.E., Muto M.G., Brooks S., Steller M., et al. The role of cytoreductive surgery in the management of stage IV epithelial ovarian carcinoma. Gynecol. Oncol. 46 (1992) 367-371
24. Eitan R., Levine D.A., Abu-Rustum N., Sonoda Y., Huh J.N., Franklin C.C., et al. The clinical significance of malignant pleural effusions in patients with optimally debulked ovarian carcinoma. Cancer 103 (2005) 1397-1401
25. Chi D.S., Franklin C.C., Levine D.A., Akselrod F., Sabbatini P., Jarnagin W.R., et al. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol. Oncol. 94 (2004) 650-654
26. Eisenhauer E.L., Abu-Rustum N.R., Sonoda Y., Levine D.A., Poynor E.A., Aghajanian C., et al. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol. Oncol. 103 (2006) 1083-1090
27. Eisenkop S.M., Friedman R.L., and Wang H.J. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol. Oncol. 69 (1998) 103-108
28. Zivanovic O., Eisenhauer E.L., Zhou Q., Iasonos A., Sabbatini P., Sonoda Y., et al. The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer. Gynecol. Oncol. 108 (2008) 287-292
29. Eisenkop S.M., and Spirtos N.M. What are the current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial ovarian cancer?. Gynecol. Oncol. 82 (2001) 489-497
30. Silver D.F. Full-thickness diaphragmatic resection with simple and secure closure to accomplish complete cytoreductive surgery for patients with ovarian cancer. Gynecol. Oncol. 95 (2004) 384-387
31. Eisenkop S.M. Thoracoscopy for the management of advanced epithelial ovarian cancer-a preliminary report. Gynecol. Oncol. 84 (2002) 315-320